07:47 AM EDT, 07/11/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) shares were down nearly 49% pre-bell Friday after the company said that the US Food and Drug Administration has required additional clinical data on deramiocel, a cell therapy candidate for cardiomyopathy in Duchenne muscular dystrophy patients.

Q32 Bio ( QTTB ) shares were 31% lower, erasing part of Thursday's rally.

Concorde International ( CIGL ) stock was down 28%, extending Thursday's slide.